AbbVie Wins Reversal of $140 Mln Verdict in Case Over AndroGel Risks AbbVie Wins Reversal of $140 Mln Verdict in Case Over AndroGel Risks

A U.S. judge on Thursday overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news